BRIEF published on 05/29/2024 at 12:35, 1 year 6 months ago Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment Obesity Treatment Pharmaceutical Advancements Transdermal Delivery Invisicare® Skinvisible
BRIEF published on 05/29/2024 at 12:35, 1 year 6 months ago Skinvisible dépose un brevet innovant contre l'obésité pour un traitement transdermique avancé Traitement De L'obésité Invisicare® Administration Transdermique Avancées Pharmaceutiques Visible Sur La Peau
PRESS RELEASE published on 05/29/2024 at 12:30, 1 year 6 months ago Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment Skinvisible Pharmaceuticals, Inc. announces a milestone in obesity treatment - a patent application using Invisicare for transdermal delivery of obesity drugs, boosting drug efficacy and adherence Patent Application Invisicare Transdermal Delivery Skinvisible Pharmaceuticals Inc. Obesity Drugs
Published on 12/05/2025 at 02:35, 4 hours 51 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 26 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 21 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 26 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 26 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 12 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
